MULTIHANCE
Total Payments
$592,864
Transactions
101
Doctors
32
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $22,044 | 38 | 7 |
| 2018 | $313,316 | 52 | 23 |
| 2017 | $257,504 | 11 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $323,398 | 14 | 54.5% |
| Royalty or License | $250,000 | 2 | 42.2% |
| Travel and Lodging | $8,706 | 36 | 1.5% |
| Food and Beverage | $5,447 | 45 | 0.9% |
| Honoraria | $5,000 | 2 | 0.8% |
| Entertainment | $311.86 | 2 | 0.1% |
Payments by Type
Research
$323,398
14 transactions
General
$269,466
87 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PARALLEL-GOUP COMPARISON OF TWO DOSES OF MULTIHANCE (0.10 MMOL/KG AND 0.05 MMOL/KG) WHEN USED FOR MAGNETIC RESONANCE IMAGING (MRI) OF THE CENTRAL NERVOUS SYSTEM (CNS) | BRACCO DIAGNOSTICS INC. | $216,028 | 2 |
| INCREASING SPATIAL RESOLUTION OF CONTRAST-ENHANCED MR ANGIOGRAPHY:UTILIZING OPTIMIZED INJECTION PROFILES | BRACCO DIAGNOSTICS INC. | $61,037 | 1 |
| EVALUATION OF REGIONAL GADOLINIUM RETENTION IN THE BRAIN USING QSM WITH CORRELATION TO REGIONAL DCE MRI PERMEABILITY USING GOCART TECHNIQUE IN INTRACRANIAL NEOPLASM PATIENTS RECEIVING GADOBENATE DIMEGLUMINE (MULTIHANCE) AND GADOTERATE MEGLUMINE (DOTAREM) | BRACCO DIAGNOSTICS INC. | $30,000 | 0 |
| PROSPECTIVE EVALUATION OF LONG-TERM EFFECTS OF REPEATED GADOLINIUM-BASED CONTRAST AGENT (GBCA) ADMINISTRATIONS OF THE SAME GBCA ON MOTOR AND COGNITIVE FUNCTIONS IN NEUROLOGICALLY NORMAL ADULTS IN COMPARISON TO A NON-EXPOSED CONTROL GROUP. | BRACCO DIAGNOSTICS INC. | $16,333 | 1 |
Top Doctors Receiving Payments for MULTIHANCE — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Diagnostic Radiology | Blacksburg, VA | $10.00 | 1 |
| , MD | Diagnostic Radiology | Greensboro, NC | $8.35 | 1 |
| , MD | Diagnostic Radiology | Greensboro, NC | $8.35 | 1 |
| , M.D | Diagnostic Radiology | Greensboro, NC | $8.35 | 1 |
| , M.D | Diagnostic Radiology | Greensboro, NC | $8.35 | 1 |
| , MD | Diagnostic Radiology | Greensboro, NC | $8.35 | 1 |
| , MD | Neuroradiology | Greensboro, NC | $8.35 | 1 |
| , MD | Diagnostic Radiology | Greensboro, NC | $8.35 | 1 |
Ad
Manufacturing Companies
- BRACCO DIAGNOSTICS INC. $592,864
Product Information
- Type Drug
- Total Payments $592,864
- Total Doctors 32
- Transactions 101
About MULTIHANCE
MULTIHANCE is a drug associated with $592,864 in payments to 32 healthcare providers, recorded across 101 transactions in the CMS Open Payments database. The primary manufacturer is BRACCO DIAGNOSTICS INC..
Payment data is available from 2017 to 2019. In 2019, $22,044 was paid across 38 transactions to 7 doctors.
The most common payment nature for MULTIHANCE is "Unspecified" ($323,398, 54.5% of total).
MULTIHANCE is associated with 4 research studies, including "A PARALLEL-GOUP COMPARISON OF TWO DOSES OF MULTIHANCE (0.10 MMOL/KG AND 0.05 MMOL/KG) WHEN USED FOR MAGNETIC RESONANCE IMAGING (MRI) OF THE CENTRAL NERVOUS SYSTEM (CNS)" ($216,028).